SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Voltaire

PatientVoltaire
Date of birth1942-11-21
IdentifiersMRN HR-EN002-SYN; SSN (made up) 000-02-5174
Document date2026-04-13
AuthorHonorine Delacroix-Mensah, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

One-week review of CT urography and kidney function; urology consultation and office cystoscopy today. [S]

History of Present Illness

Voltaire returns one week after his first visit, with the catheter in place since then. The urine in the bag has gone from red to light pink, with one small clot four days ago and none since. He has had no fever, flank pain, or bladder spasm, and the catheter has drained without blockage. He stopped the diphenhydramine and the phosphate enemas; he slept poorly for two nights and now sleeps about five hours. His bowels open every one to two days on polyethylene glycol. He takes tamsulosin each evening without dizziness. He has cut his coffee to about five cups a day. The CT urography and chest CT were done two days after the first visit. He saw Dr. Bergström-Nwosu of urology this morning, who performed a flexible cystoscopy. [S]

ElementDetail
BleedingLight pink urine; one small clot four days ago
Catheter16 Fr indwelling catheter draining well; no fever or spasm
MedicinesDiphenhydramine and phosphate enemas stopped; tamsulosin tolerated; polyethylene glycol continued
ImagingCT urography and chest CT done two days after intake
CystoscopyDone by urology this morning

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or sweats; appetite small but steady
GenitourinaryPositiveLight pink urine through the catheter; no flank pain, spasm, or leakage
GastrointestinalNegativeBowels open every one to two days; no abdominal pain
RespiratoryNegativeNo cough or blood in the sputum
CardiovascularNegativeNo dizziness on standing

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Diphenhydramine 25 mg oral capsule, one capsule at night for sleep (over the counter)One capsule at bedtimeOral route2025-09-01 to 2026-04-06stoppedS
Tamsulosin 0.4 mg oral capsule, one capsule at bedtimeOne capsule 30 minutes after the evening mealOral route2026-04-06activeS
Polyethylene glycol 3350, 17 g in a glass of water once daily17 g dissolved in water once dailyOral route2024-01-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-13Body height170cmS
2026-04-13Body weight54kgS
2026-04-13Body mass index (BMI) [Ratio]18.7kg/m2S
2026-04-13Systolic blood pressure132mm[Hg]S
2026-04-13Diastolic blood pressure70mm[Hg]S
2026-04-13Heart rate80/minS
2026-04-13Respiratory rate16/minS
2026-04-13Body temperature36.6CelS
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-13Hemoglobin [Mass/volume] in Blood11.2g/dL13.2-16.6 g/dLLowS
2026-04-13Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-04-13Urea nitrogen [Mass/volume] in Serum or Plasma22mg/dL8-24 mg/dLNormalS
2026-04-13Creatinine [Mass/volume] in Serum or Plasma1.24mg/dL0.74-1.35 mg/dLNormalS
2026-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M58mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS

Physical Exam

Vital signs recorded on 2026-04-13; see the Vital Signs section. [S]

SystemFinding
GeneralThin, alert, and lively
CardiovascularBlood pressure 132/70 mmHg seated and 128/68 mmHg standing; heart rate 80, regular
AbdomenSoft and non-tender; bladder not palpable
GenitourinaryCatheter draining light pink urine without clots; meatus clean

Problems

ProblemClinical statusVerificationCodeProvenance
Visible blood in the urine for three weeks with clots, and a weak stream, straining, and frequent small voids, in a man of 83; under evaluationactiveconfirmed R31.0S — Synthetic presenting problem echoing his documented urinary complaints and last illness; superseded by the diagnosis at the third chronic-care visit.
Chronic urinary retention with overflow (post-void residual 460 mL at intake), worsened by a nightly anticholinergic sleep aid; drained by an indwelling catheteractiveconfirmed R33.8S — Synthetic finding echoing the strangury and catheterization documented in his last weeks.
Acute kidney injury from bladder outlet obstruction (creatinine 1.68 mg/dL, from 1.1 mg/dL a year earlier)resolvedconfirmed N17.9S — Synthetic finding; it echoes, without asserting, the later encyclopedia term uremia.
Benign prostatic hyperplasia with lower urinary tract symptoms: prostate about 78 mL on CT, enlarged, firm, and smooth on examination, PSA 6.4 ng/mL with a PSA density of 0.08; no prostate biopsy, by shared decisionactiveconfirmed N40.1S — Synthetic diagnosis echoing the very large prostate described at the 1778 autopsy; whether that prostate was malignant is unknown (CLM-0012).
Chronic constipation, lifelong by his account, with long use of laxatives and self-given enemasactiveconfirmed K59.09S — Synthetic modern problem echoing his documented colic, purges, and enemas; no diagnosis of inflammatory bowel disease is made.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingUpper-tract imaging: multiphasic CT urography, with chest CTOnce, in the initial evaluation of gross hematuriaCompleted todayDone two days after intake and reviewed today: bladder mass with possible extravesical extension, clear upper tracts, no nodes; chest clear
ExaminationCystoscopyOnce, in the initial evaluation of gross hematuriaCompleted todayFlexible cystoscopy by urology today: 4 cm solid sessile tumor of the posterior wall and dome
LaboratoryUrine culture and urine cytologyOnce, in the initial evaluation of gross hematuria (cytology for gross hematuria by expert consensus)Completed todayResults from the first visit reviewed today: culture no growth; cytology atypical squamous cells suspicious for malignancy
LaboratoryKidney function and potassium after relief of obstructionWithin one to two weeks of catheter drainageCompleted todayCreatinine 1.24 mg/dL (eGFR 58), BUN 22 mg/dL, potassium 4.6 mmol/L; recovered
LaboratoryHemoglobin during gross hematuriaAt each visit while bleeding continuesCompleted today11.2 g/dL, stable from 11.6
LaboratoryPSA interpretationOnce, when it would change managementCompleted today6.4 ng/mL with a prostate of about 78 mL (density 0.08); no MRI or biopsy by shared decision
SurveyIPSSBaseline and at every follow-up visit (CMID BPH)Not indicatedNot scored while the catheter drains the bladder; 22 at intake before the catheter; next after the trial without catheter
ExaminationPost-void residualAt baseline when retention is suspected, after a trial without catheter, and when symptoms changeNot indicatedCatheter in place; 460 mL at intake; repeat after the trial without catheter
ExaminationDigital rectal examinationBaseline, then as clinically indicatedUp to dateDone at intake: enlarged, firm, smooth, no discrete nodule
Medication safetyAlpha-blocker tolerability (orthostatic blood pressure, dizziness)At 4 to 12 weeks after starting, and at each visit in a frail older adultCompleted todayNo postural drop (132/70 to 128/68 mmHg); no dizziness
Medication safetyMedication review for drugs that worsen retention or kidney functionAt intake and at each changeCompleted todayDiphenhydramine and sodium phosphate enemas stopped; no NSAIDs; no other anticholinergics
Self-managementCatheter careWhile a catheter is in placeCompleted todayLeg and night bags, hand hygiene, bag below the bladder, fluids 1.5 to 2 liters a day
ReferralUrology consultationFor gross hematuria and for retention with kidney injuryCompleted todaySeen today; resection booked in two days

Goal progress:

Guideline basis: Microhematuria: AUA/SUFU Guideline (2020; amended 2025) (2025); Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America (2009); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Prostate Cancer: Screening (2018); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026)

Follow-up: Resection in two days; chronic-care review with the pathology in about ten days; sooner for clots, a blocked catheter, or fever. Next scheduled visit 2026-04-22: review of resection pathology, diagnosis, geriatric assessment, trial without catheter, and shared decision on treatment. [S]